Introduction
============

In the last few decades, invasive fungal infections that are caused by *Candida* species have risen in parallel with the number of immunocompromised patients, such as those with AIDS, transplant recipients and cancer therapy patients ( [@B06] ). *Candida glabrata* is currently the second most common cause of candidemia in the United States ( [@B20] ). In Brazil *C. glabrata* is an emerging pathogen especially in private hospitals, attributed mainly to the use of prophylactic therapy with fluconazole ( [@B09] ; Pasqualotto *et al.* , 2009). The increased number of *C. glabrata* systemic infections is very concerning due to the high mortality rate. *C. glabrata* fungemia is frequently difficult to treat due to its intrinsic or rapidly acquired resistance to azole antifungals ( [@B20] ), which has emerged in clinical isolates from immunocompromised patients ( [@B17] ).

The treatment for *Candida* infections that show resistance to fluconazole has been the use of other antifungal azoles such as voriconazole, posaconazole and ravuconazole and other classes of antifungal agents, such as amphotericin and echinocandins ( [@B09] ; [@B18] ). However, the cross-resistance phenomenon among azoles is well-established ( [@B20] ), as well as for amphotericin ( [@B13] ) and echinocandins emergence of resistance has been detected when they are used for *C. glabrata* infection treatment ( [@B01] ; [@B16] ; [@B21] ). Combination therapy is an alternative that can be used to improve the efficacy of antimicrobial therapy for difficult-to-treat infections, either by combining different antifungals or combining antifungal and non-antifungal agents, which can decrease antimicrobial resistance ( [@B15] ).

FK506 is a calcineurin inhibitor that prevents T-cell proliferation and suppresses the immune responses that are involved in transplant rejection ( [@B07] ). Recent studies have shown that calcineurin inhibitors, such as cyclosporin A and FK506 have synergistic interactions when combined with azole antifungal agents, resulting in fungicidal activity ( [@B23] ). However, these antifungal activities against *C. glabrata* resistant isolates to azoles have not been evaluated. In this context, the aim of this study was to evaluated the *in vitro* activity of each antifungal (FLZ, KTZ, ITZ and VCR) alone and combined with FK506 against both fluconazole-susceptible and fluconazole-resistant *C. glabrata* isolates using the Clinical and Laboratory Standards Institute guidelines ( [@B08] ) standardised broth microdilution method.

Material and Methods
====================

Microorganisms
--------------

We studied two groups of *Candida glabrata* isolates. The first included thirty fluconazole-susceptible (FS) clinical isolates that were recovered from AIDS patients. The second group included thirty fluconazole-resistant isolates obtained via induction of resistance, as previously described by [@B12] . Strains were categorized as susceptible, susceptible dose dependent or resistant to fluconazole according to the interpretative breakpoints of CLSI M27-A3 criteria (≤ 8; 16--32; or ≥ 64 μg/mL respectively). All of the yeasts were identified using the commercial kit ID 32C (bioMérieux, Marcy l'Etoile, France). In addition, *Candida glabrata* (ATCC 2001) was used as quality control.

Chemicals
---------

Ketoconazole (KTZ), itraconazole (ITZ) and FK506 (Janssen-Cilag Pharmaceutica, Belgium), voriconazole (VRC) (Pfizer, Inc., New York, NY) and fluconazole (FLZ) (Sigma Chemical Co., St. Louis, MO) were obtained as standard powders. A stock solution for FLZ was prepared by dissolving the powder in distilled water, and stock solutions for the other tested drugs were prepared by dissolving ITZ, KTZ and VRC in dimethyl sulphoxide and FK506 in methanol. The stock solutions were stored at −70 °C until use.

*In vitro* susceptibility and drug interaction tests
----------------------------------------------------

Susceptibility tests were performed according to the CLSI protocol M27-A3 microdilution technique ( [@B08] ), and the highest concentrations used were 64.00 μg/mL for FK506, 512.00 μg/mL for fluconazole and 32.00 μg/mL for other the azoles. The interaction between FK506 and the azoles against thirty strains each of fluconazole-susceptible and -resistant *C. glabrata* was evaluated using the microdilution checkerboard method. Drug dilutions were prepared in order to obtain four times the final concentrations, and 50 μL of each concentration of azoles was added to columns 1 to 10 and 50 μL of each concentration of FK506 was added to rows A to G. The concentrations of FK506 ranged from 0.25 μg/mL to 32.00 μg/mL, and the concentrations of the azole antifungals ranged from 0.03 μg/mL to 256.00 μg/mL. The experiment was tested in triplicate. The fractional inhibitory concentration (FIC) was calculated for each agent by dividing the minimal inhibitory concentration (MIC) of each drug in combination by the MIC of the drug alone. The FIC values were then totalled to determine the fractional inhibitory concentration index (FICI) that resulted from the drug combinations, as the following equation: FICI=FIC ~A~ +FIC ~B~ = C ~A~ ^Comb^ /MIC ~A~ ^Alone^ + C ~B~ ^Comb^ /MIC ~B~ ^Alone^ , where MIC ~A~ ^Alone^ and MIC ~B~ ^Alone^ are the MICs of drugs A and B when acting alone and C ~A~ ^Comb^ and C ~B~ ^Comb^ are the concentrations of drugs A and B when combined. Synergism was defined as an FICI ≤ 0.5, indifference was defined as 1.0 \< FICI ≤ 4, and antagonism was defined as FICI \> 4 ( [@B14] ). The statistical analysis of combinations was performed using one-way ANOVA followed by post-hoc Tukey's test. The statistical analysis used to evaluate the different groups (susceptible strains *vs.* resistant strains) when antifungal acting alone was T test. In all the statistical tests, it was considered a significance level of 5% (p ≤ 0.05).

Results
=======

Based on the parameters of susceptibility (MIC range, MIC ~50~ , MIC ~90~ and geometric mean), as shown in [Table 1](#t01){ref-type="table"} , fluconazole-susceptible (FS) strains showed lower MICs to ketoconazole (0.13--2.00 μg/mL), itraconazole (0.50--8.00 μg/mL), voriconazole (0.13--4.00 μg/mL) and fluconazole (1.00--32.00 μg/mL) compared to fluconazole-resistant (FR) strains, which showed MIC ranges of 0.50--16.00 μg/mL for ketoconazole, 1.00--16.00 μg/mL for itraconazole, 1.00--16.00 μg/mL for voriconazole and 64.00--256.00 μg/mL for fluconazole.

###### Susceptibility (μg/mL) of thirty fluconazole-susceptible (FS) and fluconazole-resistant (FR) *Candida glabrata* strains to fluconazole, ketoconazole, itraconazole and voriconazole.

  Agents         Group of isolates   Geometric mean   MIC Range       MIC ~50~   MIC ~90~
  -------------- ------------------- ---------------- --------------- ---------- ----------
  Fluconazole    FS                  5.039            1.00--32.00     4.00       32.00
                 FR                  147.033          64.00--256.00   128.00     256.00
  Ketoconazole   FS                  0.536            0.13--2.00      0.50       1.00
                 FR                  2.579            0.50--16.00     2.00       8.00
  Itraconazole   FS                  1.203            0.50--8.00      1.00       4.00
                 FR                  3.402            1.00--16.00     4.00       8.00
  Voriconazole   FS                  0.478            0.13--4.00      0.50       1.00
                 FR                  2.639            1.00--16.00     2.00       8.00

MIC ~50~ : Mean the concentration at which 50% of tested strain cannot grow.

MIC ~90~ : Mean the concentration at which 90% of tested strain cannot grow.

The statistical analysis showed significant differences between the susceptibility of FS *vs.* FR groups for all azole antifungal (p \< 0.0001 (FLZ); p \< 0.0023 (KTZ); p \< 0.01 (ITZ and VCR)). Because *C. glabrata* fluconazole-resistant (FR) strains showed an increase in the MIC for all antifungal agents, cross-resistance appears to occur between fluconazole and the other azoles. FK506 did not show activity against FS and FR strains at the highest concentration tested. [Table 2](#t02){ref-type="table"} shows the percentages of synergism, indifference and antagonism that resulted from the combinations of FK506 with ketoconazole, itraconazole, voriconazole and fluconazole against the FS and FR group.

###### Percentages of synergism, indifference and antagonism that resulted from the combinations of tacrolimus (FK506) with fluconazole (FLZ), ketoconazole (KTZ), itraconazole (ITZ) and voriconazole (VRC) against fluconazole-susceptible (FS) and fluconazole-resistant (FR) *Candida glabrata* strains.

  Agents        Group of isolates   Interactions (%)           
  ------------- ------------------- ------------------ ------- -------
  FLZ + FK506   FS                  3.33               50.00   46.67
                FR                  60.00              40.00   0.00
  KTZ + FK506   FS                  37.00              63.00   0.00
                FR                  77.00              23.00   0.00
  ITZ + FK506   FS                  43.00              57.00   0.00
                FR                  73.00              27.00   0.00
  VRC + FK506   FS                  43.00              57.00   0.00
                FR                  63.00              37.00   0.00

FK506 combined with ketoconazole against the FR strains showed 77% of synergism, followed by the combinations with itraconazole (73%), voriconazole (63%) and fluconazole (60%). These results showed that the percentages for the synergistic interactions against the FR strains were significantly similar for the four azoles (p \< 0.0001). In contrast, the FS group showed lower synergism percentages for both voriconazole and itraconazole combined with FK506 (43%) as well as for the combination with ketoconazole (37%); these combinations didn't differ. (p \< 0.0001). The combination with fluconazole showed a minimal synergic interaction (3.33%). The percentages of indifference were similar for the four combinations (approximately 56% with FS group, 38% (FLZ and VRC) and 25% (ITZ and KTZ) with FR group). Antagonism effects were not detected for combinations with ketoconazole, itraconazole and voriconazole, however the combination with fluconazole showed 46.67% to FS strains.

Discussion
==========

Invasive fungal infections are a significant complication in transplant patients, and 62% to 91% of these infections are caused by *Candida* species *.* In liver transplants, the manipulation of the gastrointestinal tract can translocate this microorganism through the intestinal epithelium, resulting in the development of invasive candidiasis ( [@B22] ).

FK506 is one of the most common and efficient immunosuppressants used to prevent transplant rejection ( [@B17] ). This compound inhibits calcineurin, a phosphatase protein involved in lymphocyte activation that is responsible for the synthesis of cytokines, such as interleukin-2, and is primarily involved in NFAT (nuclear factor of activated T-cells) regulation. Calcineurin is activated by an increase in cytoplasmic Ca ^2+^ , and its inhibition by immunosuppressants blocks the activation of T lymphocytes, which is critical for an immune response ( [@B04] ).

Calcineurin governing fungal physiology, including the regulation of cell cycle progression, cation homeostasis, cell wall biosynthesis, antifungal drug resistance and virulence ( [@B07] ). Immunosuppressants inhibit calcineurin function in several fungal species, including *Candida albicans* , *Cryptococcus neoformans* , and *Aspergillus fumigatus,* affecting essential functions in cell fungal ( [@B03] ).

Azole antifungals stimulate calcium influx and this activates the calcium signalling pathway, which is essential for yeast survival ( [@B03] ). In *C. albicans,* calcineurin inhibition results in greater susceptibility to azole antifungal agents ( [@B24] ), due to the high level of stress that is caused by influx of cations such as Ca ^2+^ and Na ^2+^ in the fungal cell ( [@B07] ). Here, we showed that the combination of FK506 with azoles can show synergism against fluconazole-susceptible and -resistant *C. glabrata* strains.

[@B17] demonstrated a synergistic effect with the combination of terbinafine and FK506 against *Candida glabrata* , and [@B24] showed that the activity of azole antifungal agents against *C. albicans* can be enhanced by FK506. [@B11] proposed that the immunosuppressant FK506 and cyclosporin analogues can be effective in combination with azoles for the treatment of invasive infections that are caused by *Candida spp* , which is in agreement with the present study showing that calcineurin inhibition can function as an adjuvant for treating invasive *Candida glabrata* infections.

Novel antifungal agents, such as posaconazole and echinocandins, have also been ineffective in the treatment of candidemias that is caused by *C. glabrata,* and susceptibility tests have confirmed drug resistance to posaconazole in these isolates ( [@B02] ). Among echinocandins, decreased *in vitro* susceptibility and resistance has been observed in *C. glabrata* strains with single *fks1* or *fks2* mutations, or both ( [@B01] ; [@B16] ). [@B21] reported a study were thereabout, 11% of *C. glabrata* fluconazole-resistant isolates were also resistant to one or more echinocandins, all of which contained an acquired mutation in *fks1* or *fks2* .

In conclusion, we demonstrated that the rates of synergism were higher among fluconazole-resistant isolates than those observed with fluconazole-sensitive *C. glabrata* isolates. Our results confirm that combinations of FK506 and azole antifungal agents may be promising and warrant further studies *in vivo* using an experimental *C. glabrata* infection.
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